Comparative Pharmacology
Head-to-head clinical analysis: FLUPHENAZINE DECANOATE versus TARACTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUPHENAZINE DECANOATE versus TARACTAN.
FLUPHENAZINE DECANOATE vs TARACTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluphenazine decanoate is a long-acting phenothiazine antipsychotic. It exerts its effects by blocking postsynaptic dopamine D2 receptors in the mesolimbic pathway, and also has antagonistic activity at alpha-1 adrenergic, muscarinic, and histamine H1 receptors, contributing to its side effect profile.
Thioxanthene antipsychotic; blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system; also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
12.5-25 mg deep IM injection every 2-4 weeks, not exceeding 100 mg per dose.
Oral: 25-50 mg three times daily, increased as needed to 400-600 mg/day. IM: 12.5-25 mg every 6-8 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 14 days (range 7-21 days) following IM injection, reflecting slow release from depot and prolonged redistribution.
Terminal elimination half-life is approximately 20-40 hours (mean 30 hours). Steady-state reached in 5-7 days.
Primarily renal (metabolites) and fecal (biliary). Estimated 50% renal, 50% fecal as metabolites.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Metabolites eliminated renally (30%) and fecally (70%).
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic